Robert A. Hazlitt

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss

Tal Teitz, Jie Fang, Asli N. Goktug et al. · The Journal of Experimental Medicine · 2018 · 99 citations · Full text

Cell Death, Glioma, Oxidative Stress +21

AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss

Santanu Hati, Marisa Zallocchi, Robert A. Hazlitt et al. · European Journal of Medicinal Chemistry · 2021 · 41 citations · Full text

Selective Cdk2 Degrader, Audiology, Molecular Biology +7

Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss

Robert A. Hazlitt, Tal Teitz, Justine D. Bonga et al. · Journal of Medicinal Chemistry · 2018 · 36 citations · Full text

Cisplatin-induced Hearing Loss, Medicinal Chemistry, Chemoprevention Strategy +14

Conversion of methyl ketones and methyl sulfones into α-deutero-α,α-difluoromethyl ketones and α-deutero-α,α-difluoromethyl sulfones in three synthetic steps

Munia F. Sowaileh, Changho Han, Robert A. Hazlitt et al. · Tetrahedron Letters · 2016 · 24 citations · Full text

Chemical Engineering, Synthetic Steps, Engineering +9

Optimized synthesis of a pentafluoro- gem -diol and conversion to a CF2Br -glucopyranose through trifluoroacetate-release and halogenation

Robert A. Hazlitt, Jinu P. John, Que-Lynn Tran et al. · Tetrahedron Letters · 2016 · 14 citations · Full text

Pentafluoro- Gem -Diol, Engineering, Cf2br -Glucopyranose +5